Dermatology

Our Dermatology portfolio spans a large range of high quality, clinically-proven skin care brands for dry skin, fungal & bacterial infections and anti-aging. Our Dermatology brands are focused to specialist doctors in Dermatology.

Xerocare^™

Xerocare derives its name from the condition it takes care of viz. Xerosis or dry skin.
Xerocare redefines moisturization as it brings together the success of well accepted agents – Squalene – a natural moisturizer, Aloe Vera – a natural soothing, moisturizing and healing agent and Vitamin E – an antioxidant which protects cell membranes. Xerocare thus provides moisturizing benefits and also enlivens the skin.
For ease of application depending on severity and affected surface area, Xerocare is available in two formulations - Xerocare cream and Xerocare lotion.
In Xerosis, Xerocare is ideal as it truly gives a moisturizing PLUS effect.

Baclytic^™

Baclytic is the combination of choice for treatment of acne.
Adapalene is a third generation topical retinoid and Clindamycin which is effective against gram positive and anaerobic bacteria in Baclytic are two well established agents for the treatment of acne.
These two agents working in tandem bring about a potent effect to treat acne swiftly by reducing P. acnes count and by inhibiting inflammation caused by bacteria.
Baclytic is available as a pack of 15 gm gel.

Atopiclair^™

Atopiclair™ is a hydrolipidic skin barrier treatment that is clinically proven in randomized, double blind, controlled clinical trial programs to provide effective symptomatic relief and control of atopic dermatitis.
Atopiclair™ is a well-tolerated, effective and corticosteroid-free option for the management of mild to moderate atopic dermatitis for infants, children and adults. Its key ingredients work in a multifactorial manner to calm the skin, repair and protect the skin barrier. It is safe for long term usage in the management of atopic dermatitis.
Randomized, Double-Blind, Controlled Trial Results:
Children¹ (n = 142 subjects)
77% treatment success vs 0% vehicle3 (p<0.0001)
78% improvement in itch score4 (p<0.0001)
91% of Atopiclair patients did not require steroid rescue medication during the study (p<0.005)
Adults² (n = 218 subjects)
75% improvement in EASI score vs 13% vehicle5 (p<0.0001)
82% improvement in itch score6 (p<0.0001)
94% of Atopiclair patients did not require steroid rescue medication during the study (p<0.0001)
References:
¹Boguniewicz et al. J Pediatr 2008; 152(6):854-9.
²Abramovitis et al. J Drugs Dermatol 2006; 5(3):236-244.
³Primary Endpoint: IGA (Investigator's Global Assessment) at Day 22. 77% of Atopiclair group achieved treatment success (IGA Score 0 or 1). 0% of vehicle population achieved treatment successes.
⁴Atopiclair group showed early and lasting improvements in itch. Mean itch score improved by Day 3, 78% by Day 43. Significantly greater improvement in itch was reported with Atopiclair vs. vehicle at all time points.
⁵Atopiclair 75% improvement in EASI (Eczema Area and Severity Index) score in Atopiclair group vs 13% in vehicle group at the end of the study.
⁶82% improvement in itch score in the Atopiclair group at the end of the study. Itch improved early and showed continuous improvement

Papulex^™

Papulex™ is a specially formulated line of products that keep acne prone skin in good condition through cleansing, treating and protecting. Well supported by clinical studies, Papulex™ is effective with its recognized functional ingredients. Nicotinamide and Anti-Bacterial Adhesive substance (ABA's) eliminate blemishes, and Zinc PCA helps to reduce sebum secretion.
Non comedogenic and non photosensitizing, Papulex™ can be used alone or in combination with conventional acne treatments during the day and night. Available as a Soap Free Cleansing Gel and Oil-free Cream Papulex™ offers a complete daily management solution for acne prone skin.